Cargando…

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review

Detalles Bibliográficos
Autores principales:	Abduelmula, Abrahim, Mufti, Asfandyar, Chong, Derrick H.Y., Sood, Siddhartha, Prajapati, Vimal H., Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596715/ https://www.ncbi.nlm.nih.gov/pubmed/36311913 http://dx.doi.org/10.1016/j.jdin.2022.09.001

Ejemplares similares

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2023)

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Intravenous immunoglobulins in infantile dyshidrosiform bullous pemphigoid refractory to steroids and dapsone
por: Viglizzo, Gianmaria, et al.
Publicado: (2022)

Biological treatment for bullous pemphigoid
por: Oren-Shabtai, Meital, et al.
Publicado: (2023)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

New‐onset bullous pemphigoid and flare of pre‐existing bullous pemphigoid after the third dose of the COVID‐19 vaccine
por: Bardazzi, Federico, et al.
Publicado: (2022)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Bullous pemphigoid and COVID-19 vaccine()
por: Pérez-López, Israel, et al.
Publicado: (2021)

Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid
por: Zhou, Tong, et al.
Publicado: (2021)

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
por: WANG, Qijun, et al.
Publicado: (2023)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

Bullous Pemphigoid and Other Pemphigoid Dermatoses
por: Pratasava, Valeryia, et al.
Publicado: (2021)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Increasing evidence for omalizumab in the treatment of bullous pemphigoid
por: Lonowski, Sarah, et al.
Publicado: (2020)

Resolution in bullous pemphigoid
por: Sadik, Christian D., et al.
Publicado: (2019)

Esophageal Bullous Pemphigoid
por: Castelo Branco, Catarina, et al.
Publicado: (2022)

Dyshidrosiform Bullous Pemphigoid
por: Cohen, Philip R.
Publicado: (2021)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

Cutaneous Dermatophytosis Mimicking Bullous Pemphigoid or Typical Bullous Pemphigoid and Tinea Incognito?
por: Andrés, Tirado-Sánchez, et al.
Publicado: (2019)

When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence
por: Hopkins, Christina R, et al.
Publicado: (2022)

UVB-induced bullous pemphigoid in a patient with psoriasis
por: Ceryn, Justyna, et al.
Publicado: (2020)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2020)

Reverse Koebner Phenomenon in Bullous Pemphigoid – A Case Report
por: Mohapatra, Liza, et al.
Publicado: (2019)

Immunoglobulin M bullous pemphigoid: An enigma
por: Baardman, Rosalie, et al.
Publicado: (2020)

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

LOCALIZED FLEXURAL BULLOUS PEMPHIGOID
por: Mehta, Vandana, et al.
Publicado: (2008)

Coexistence of psoriasis with bullous pemphigoid
por: Rao, Raghavendra, et al.
Publicado: (2012)

Pembrolizumab-induced bullous pemphigoid
por: Sun, Christina W., et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Bullous Pemphigoid Mimicking Cellulitis
por: Ivyanskiy, Ilya, et al.
Publicado: (2021)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oulk9288ji8nj31a2cia4gum59